A Comprehensive Review of Rapid-Onset Opioids for Breakthrough Pain
Author:
Open Access
- 1 June 2012
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 26 (6) , 509-535
Abstract
Breakthrough pain (BTP) is a transitory pain (reaching maximum severity in ∼15 minutes and lasting ∼60 minutes in patients with cancer) that occurs despite the management of chronic pain with...Keywords
This publication has 80 references indexed in Scilit:
- Consistency of Efficacy, Patient Acceptability, and Nasal Tolerability of Fentanyl Pectin Nasal Spray Compared with Immediate-Release Morphine Sulfate in Breakthrough Cancer PainJournal of Pain and Symptom Management, 2011
- Single-Dose Pharmacokinetics of Fentanyl Buccal Soluble FilmPain Medicine, 2010
- Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled studyAnnals of Oncology, 2009
- Formulation Selection and Pharmacokinetic Comparison of Fentanyl Buccal Soluble Film with Oral Transmucosal Fentanyl CitrateClinical Drug Investigation, 2009
- Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough painBritish Journal of Cancer, 2007
- Comparison of Equivalent Doses of Fentanyl Buccal Tablets and Arteriovenous Differences in Fentanyl PharmacokineticsClinical Pharmacokinetics, 2006
- Pharmacokinetic–Pharmacodynamic Modeling of OpioidsJournal of Pain and Symptom Management, 2005
- Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositisSupportive Care in Cancer, 2004
- Peak Plasma Concentrations After Oral MorphineJournal of Pain and Symptom Management, 1998
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996